Generic Biologic Bill Needs Clinical Data Requirements, Sen. Hatch Says
This article was originally published in The Pink Sheet Daily
Executive Summary
At Senate hearing, co-author of ANDA legislation says that FDA should require clinical trials from sponsors seeking follow-on biologic approval.